Эплеренон – селективный блокатор рецепторов альдостерона


Л.О. Минушкина, Д.А. Затейщиков

Эплеренон - селективный блокатор рецепторов альдостерона
Рассматривается роль альдостерона в патогенезе сердечно-сосудистых заболеваний, что определяет значение блокаторов его рецепторов в лечении указанной патологии. Первым селективным блокатором рецепторов альдостерона стал эплеренон. В обзоре представлены фармакологические свойства эплеренона, результаты его экспериментальных исследований. Приводятся данные о применении эплеренона в лечении артериальной гипертензии, сердечной недостаточности, острого инфаркта миокарда (исследование EPHESUS). Таким образом, появился новый препарат, который позволяет блокировать активность альдостерона и отличается лучшей, чем спиронолактон, переносимостью. Основными сферами применения эплеренона станут лечение артериальной гипертензии и сердечной недостаточности, а также использование у больных, перенесших инфаркт миокарда, в качестве средства вторичной профилактики.

Литература






  1. McMachon E. Recent studies with eplerenone, a novel selective aldosterone receptor antagonist. Curr Opin Pharmacol 2001;1:190–96.

  2. Silvestre J-S, Heymes C, Oubenaissa A, et al. Activation of cardiac aldosterone production in rat myocardial infarction: effect of angiotensin II receptor blockade and role in cardiac fibrosis. Circulation 1999;99:2694–701.

  3. Seckl JR, Walker BR. Minireview: 11beta-hydroxysteroid dehydrogenase type 1 – a tissue-specific amplifier of glucocorticoid action. Endocrinology 2001;142:1371–76.

  4. Takeda Y, Miyamori I, Yoneda T, et al. Expression of 11 beta-hydroxysteroid dehydrogenase mRNA in rat vascular smooth muscle cells. Life Sci 1994;54:281–85.

  5. Karin M. New twists in gene regulation by glucocorticoid receptor: is DNA binding dispensable? Cell 1998;93:487–90.

  6. Helman SI, Liu X, Baldwin K, et al. Time-dependent stimulation by aldosterone of blocker-sensitive ENaCs in A6 epithelia. Am J Physiol Cell Physiol 1998;274:C947–C957.

  7. Booth E, Johnson JP, Stockand JD. Aldosterone. Adv Physiol Educ 2002;26:8–23. Schunkert H, Hense HW, Danser J, et al. Association between circulating components of the rennin-angiotensine-aldosterone system and left ventricular mass. Br Heart J 1997;77:24–31.

  8. Falkenstein E, Tillmann HC, Christ M, et al. Multiple actions of steroid hormones – a focus on rapid, nongenomic effects. Pharmacol Rev 2000;52:513–56.

  9. Danser A, Cha W. Cardioprotective effects of eplerenone in the rat heart: interaction with locally synthesized or blood-derived aldosterone? The FASEB Journal 2006;20:A342–A343.

  10. Duprez KT, Bauwens FR, Buyzere ML, et al. Influence of aeterial blood pressure and aldosterone on left ventricular hypertrophy in moderate essential hypertension. Am J Cardiol 1993;71: 17A–20A.

  11. Schunkert H, Hense HW, Danser J, et al. Association between circulating components of the rennin-angiotensine-aldosterone system and left ventricular mass. Br Heart J 1997;77:24–31.

  12. Минушкина Л.О., Затейщикова А.А., Хотченкова Н.В. и др. Активность ренин-альдостероновой системы и особенности структуры и функции левого желудочка у больных артериальной гипертонией // Кардиология. 2000. № 9. С. 23–27.

  13. Sato A, Funder JW. High glucose stimulates aldosterone-induced hypertrophy via type I mineralocorticoid receptors in neonatal rat cardiomyocytes. Endocrinol 1996;137:4145–53.

  14. Tsutamoto T, Wadw A, Maeda K, et al. Effect of spironolactone on Plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure. J Am Col Cardiol 2001;37:1228–33.

  15. Zannand F, Alla F, Dousset B, et al. Limination of excessive extracellular matrix turnover may contribute to survaival benefit of spironolacton therapy in patients with congestive heart failure. Insifhts from the randomized aldactone evaluated study (Rales). Circulation 2000;102:2700–06.

  16. McFaiden R, Barr C, Struthers A. Aldosterone blocade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients Cardiovasc. Research 1997;35:30–34.

  17. Blacher J, Amah G, Girerd X, et al. Association between increased plasma levels of aldosterone and decreased systemic arterial compliance in subjects with essential hypertension. Am J Hypertens 1997;10:1326–34.

  18. Duprez D, De Buyzere M, Rietzschel ER, et al. Aldosterone and vascular damage. Curr Hypertens Rep 2000;2:327–34.

  19. Farquharson CAJ, Struthers AD. Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I / angiotensin II conversion in patients with chronic heart failure. Circulation 2000;101:594–97.

  20. Struthers AD. Pathophysiology of aldosterone and its antagonists. Fundam Clin Pharmacol 2000;14:549–52.

  21. Brown NJ, Kim KS, Chen YQ, et al. Synergistic effect of adrenal steroids and angiotensin II on plasminogen activator inhibitor-1 production. J Clin Endocrinol Metab 2000;85:336–44.

  22. Brown NJ, Agirbasli MA, Williams GH, et al. Effect of activation and inhibition of the renin-angiotensin system on plasma PAI-1. Hypertension 1998;32:965–71.

  23. Brown NJ, Nakamura S, Ma L, et al. Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo. Kidney Int 2000; 58:1219–27.

  24. Pitt B, Zannand F, Remme W, et al. The effect of spirinilactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999;341:709–17.

  25. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult. J Am Coll Cardiol 2005;46:1–82.

  26. Delyani J, Myles K, Funder J, et al. Eplerenone (SC 66110), a highly selective aldosteron antagonist. Am J Hypertens 1998;11:94A.

  27. deGasparo M, Joss U, Ramjoue, et al. Three new epoxy-spironolactone derivates: characterization in vivo and in vitro. J Pharmacol Exp Ther 1987;240:650–56.

  28. Cook CS, Berry LM, Kim DH, et al. Involvement of CYP3A in the metabolism of eplerenone in humans and dogs: differential metabolism by CYP3A4 and CYP3A5. Drug Metab Dispos 2002;30(12):1344–51.

  29. Rocha R, Chander P, Zuckerman A, et al. Role of mineralocorticoids in renal injury in stroke-phone hypertensive rats. Hypertension 1998;32:598.

  30. Blasi ER, Rocha R, Rudolph AE, et al. Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats. Kidney Int 2003;63:1791–800.

  31. Burla AK, Neves MF, Oigman W, et al. Eplerenone offsets cardiac and aortic adverse remodeling in spontaneously hypertensive rats. Int J Cardiol 2007;114(1):64–70.

  32. Rajagopalan S, Duquaine D, King S, et al. Mineralocorticoid receptor antagonism in experimental atherosclerosis. Circulation 2002;105: 2212–16.

  33. Ward M, Kanellakis P, Ramsey D. Eplerenone suppresses constrictive remodeling and collagen accumulation after angioplasty in porcine coronary arteries Circulation 2001;104:467–72.

  34. Lacolley P, Labat C, Pujol A, et al. Increased carotid wall elastic modulus and fibronectin in aldosterone-salt-treated rats: effects of eplerenone. Circulation 2002;106:2848–53.

  35. Rocha R, Rudolph AE, Frierdich GE, et al. Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol Heart Circ Physiol 2002;283:H1802–1810.

  36. Delyani JA, Robinson EL, Rudolph AE. Effect of a selective aldosterone receptor antagonist in myocardial infarction. Am J Physiol Heart Circ Physiol 2001;281:H647–654.

  37. Suzuki G, Morita H, Mishima T, et al. Effects of long-term monotherapy with eplerenone, a novel aldosterone blocker,on progression of left ventricular dysfunction and remodeling in dogs with heart failure. Circulation 2002;106: 2967–72.

  38. Rocha R, Stier C., Kifor I, et al. Aldosterone: A Mediator of Myocardial Necrosis and Renal Arteriopathy. Endocrinol 2000;141:3871–78.

  39. Shroff SC, Ryu K, Martovitz NL, et al. Selective aldosterone blockade suppresses atrial tachyarrhythmias in heart failure. J Cardiovasc Electrophysiol 2006;17(5):534–41.

  40. Oberleithner H, Riethmuller C, Ludwig T, et al. Aldosterone remodels human endothelium. Acta Physiol (Oxf) 2006;187(1–2):305–12.

  41. Weinberger MH, Roniker B, Krause SL, et al. Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. Am J Hypertens 2002;15:709–16.

  42. Epstein M, Alexander JC, Roniker B. Efficacy and safety of eplerenone, a novel and selective aldosterone receptor antagonist (SARA), in patients with mild-to-moderate hypertension. Hyperetension 1999;33:1075.

  43. Levy DG, Rocha R, Funder JW. Distinguishing the Antihypertensive and Electrolyte Effects of Eplerenone. J Clin Endocrinol Metab 2004;89: 2736–40.

  44. Pitt B, Reichek N, Willenbrock R, et al. Effects of Eplerenone, Enalapril, and Eplerenone/Enalapril in Patients With Essential Hypertension and Left Ventricular Hypertrophy The 4E–Left Ventricular Hypertrophy Study. Circulation 2003; 108:1831–38.

  45. Krum H., Nolly H, Roniker B, et al. Coadministration of eplerenon with an angiotensin converting enzyme inhibitor or an angiotensine II blocer in patients with mild or moderate hypertension. Eur Heart J 2001;22:612.

  46. Flack JM, Oparil S, Pratt JH, et al. Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients. J Am Coll Cardiol 2003;41:1148–55.

  47. White WB, Duprez D, Hillaire R. Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. Hypertension 2003;41:1021–26.

  48. Weinberger MH, White WB, Ruilope L-M, et al. Effects of Eplerenone Versus Losartan in Patients With Low-Renin Hypertension. Am Heart J 2005;150(3):423–33.

  49. Saruta T, Kageyama S, Ogihara T. Efficacy and Safety of the Selective Aldosterone Blocker Eplerenone in Japanese Patients With Hypertension: A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study. J Clin Hypertens 2004;6(4):175–85.

  50. Barclay L, Lie D. Eplerenone Well Tolerated in Older Patients. Arch Intern Med 2003; 163: 1543–48.

  51. White WB, Duprez D, St Hillaire R, et al. Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. Hypertension 2003;41(5): 1021–26.

  52. 2003 European Society of Hypertension–European Society of Cardiology guidelines for the management of arterial Hypertension (Guidelines Committee). J Hypertension 2003;21: 1011–53.

  53. Pitt B, Roniker B. Eplerenone, a novel selective aldosteron receptor antagonist (SARA): dose – finding study in patients with heart failure. J Am Coll Cardiol 1999;33:188A–189A.

  54. Pitt B, Remme W, Zannad F, et al. Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial Infarction. N Engl J Med 2003;348:1309–21.

  55. Pitt B, White H, Nicolau J, et al. Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. J Am Coll Cardiol 2005;46(3):425–31.

  56. Pitt B, Gheorghiade M, Zannad F, et al. Evaluation of eplerenone in the subgroup of EPHESUS patients with baseline left ventricular ejection fraction or=30 %. Eur J Heart Fail 2006; 8(3):295–301.

  57. Szucs TD, Holm MV, Schwenkglenks M, et al. Cost-effectiveness of eplerenone in patients with left ventricular dysfunction after myocardial infarction – an analysis of the EPHESUS study from a Swiss perspective. Cardiovasc Drugs Ther 2006;20(3):193–204.

  58. Beygui F, Collet J-P, Benoliel J-J, et al. High Plasma Aldosterone Levels on Admission Are Associated With Death in Patients Presenting With Acute ST-Elevation Myocardial Infarction. Circulation 2006;114:2604–10.

  59. Zannad F, Ketelslegers J-M, Schiffrin EL, et al. The effect of eplerenone on markers of cardiac fibrosis: insights from EPHESUS (abstr). J Am Coll Cardiol 2004;43(Suppl. A):200A.

  60. Antman, et al. Management of Patients With STEMI: Executive Summary. J Am Coll Cardiol 2004;44:671–719.




Бионика Медиа